Abstract:Tumor cells are known to upregulate major histocompatibility complex-class I chain related proteins A and B (MICA/B) expression under stress conditions or due to radiation exposure. However, it is not clear whether there are specific stages of cellular maturation in which these ligands are upregulated or whether the natural killer (NK) cells differentially target these tumors in direct cytotoxicity or antibody-dependent cell cytotoxicity (ADCC). We used freshly isolated primary and osteoclast (OCs)-expanded NK cells to determine the degree of direct cytotoxicity or of ADCC using anti-MICA/B monoclonal antibodies (mAbs) against oral stem-like/poorly-differentiated oral squamous cancer stem cells (OSCSCs) and Mia PaCa-2 (MP2) pancreatic tumors as well as their well-differentiated counterparts: namely, oral squamous carcinoma cells (OSCCs) and pancreatic PL12 tumors. By using phenotypic and functional analysis, we demonstrated that OSCSCs and MP2 tumors were primary targets of direct cytotoxicity by freshly isolated NK cells and not by ADCC mediated by anti-MICA/B mAbs, which was likely due to the lower surface expression of MICA/B. However, the inverse was seen when their MICA/B-expressing differentiated counterparts, OSCCs and PL12 tumors, were used in direct cytotoxicity and ADCC, in which there was lower direct cytotoxicity but higher ADCC mediated by the NK cells. Differentiation of the OSCSCs and MP2 tumors by NK cell-supernatants abolished the direct killing of these tumors by the NK cells while enhancing NK cell-mediated ADCC due to the increased expression of MICA/B on the surface of these tumors. We further report that both direct killing and ADCC against MICA/B expressing tumors were significantly diminished by cancer patients’ NK cells. Surprisingly, OC-expanded NK cells, unlike primary interleukin-2 (IL-2) activated NK cells, were found to kill OSCCs and PL12 tumors, and under these conditions, we did not observe significant ADCC using anti-MICA/B mAbs, even though the tumors expressed a higher surface expression of MICA/B. In addition, differentiated tumor cells also expressed higher levels of surface epidermal growth factor receptor (EGFR) and programmed death-ligand 1(PDL1) and were more susceptible to NK cell-mediated ADCC in the presence of anti-EGFR and anti-PDL1 mAbs compared to their stem-like/poorly differentiated counterparts. Overall, these results suggested the possibility of CD16 receptors mediating both direct cytotoxicity and ADCC, resulting in the competitive use of these receptors in either direct killing or ADCC, depending on the differentiation status of tumor cells and the stage of maturation and activation of NK cells.

CD56 DIRECTLY INTERACTS IN THE PROCESS OF NCAM-POSITIVE TARGET CELL-KILLING BY NK CELLS

CD2AP is indispensable to multistep cytotoxic process by NK cells.

The Adaptor Protein Nck Interacts with Fas Ligand: Guiding the Death Factor to the Cytotoxic Immunological Synapse

Human NK cells responses are enhanced by CD56 engagement

Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity

Research on the effects of CD137 signaling on the function of CD3−CD56+NK cells

Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells

Regulation of Activated Cd4(+) T Cells by Nk Cells Via the Qa-1-Nkg2a Inhibitory Pathway

Distinct CD16a features on human NK cells observed by flow cytometry correlate with increased ADCC

Neutrophil CD16b Crosslinking Induces Lipid Raft-Mediated Activation of SHP-2 and Affects Cytokine Expression and Retarded Neutrophil Apoptosis

CD226 Protein is Involved in Immune Synapse Formation and Triggers Natural Killer (NK) Cell Activation Via Its First Extracellular Domain*

CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells

Regulation of Natural Killer cell cytotoxicity by shedding of the Fc receptor CD16

CD137 Enhances Cytotoxicity of CD3(+)CD56(+) Cells and Their Capacities to Induce CD4(+) Th1 Responses.

Receptor-induced death in human natural killer cells: involvement of CD16.

Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer Cells

Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes

CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells

Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes.

ADCC against MICA/B Is Mediated against Differentiated Oral and Pancreatic and Not Stem-Like/Poorly Differentiated Tumors by the NK Cells; Loss in Cancer Patients due to Down-Modulation of CD16 Receptor

Tumor-derived soluble CD155 inhibits DNAM-1–mediated antitumor activity of natural killer cells